company background image
MDA

MedApp WSE:MDA Stock Report

Last Price

zł0.54

Market Cap

zł135.1m

7D

-5.3%

1Y

-44.2%

Updated

10 Aug, 2022

Data

Company Financials +
MDA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth6/6
Past Performance2/6
Financial Health6/6
Dividends0/6

MDA Stock Overview

MedApp S.A. develops mobile solutions for medicine in Poland.

MedApp Competitors

Price History & Performance

Summary of all time highs, changes and price drops for MedApp
Historical stock prices
Current Share Pricezł0.54
52 Week Highzł1.51
52 Week Lowzł0.37
Beta0.55
1 Month Change-6.90%
3 Month Change0%
1 Year Change-44.22%
3 Year Change-39.67%
5 Year Change-50.00%
Change since IPO500.00%

Recent News & Updates

Mar 26
Why Investors Shouldn't Be Surprised By MedApp S.A.'s (WSE:MDA) 26% Share Price Surge

Why Investors Shouldn't Be Surprised By MedApp S.A.'s (WSE:MDA) 26% Share Price Surge

MedApp S.A. ( WSE:MDA ) shareholders are no doubt pleased to see that the share price has bounced 26% in the last...

Shareholder Returns

MDAPL Healthcare ServicesPL Market
7D-5.3%-1.0%0.1%
1Y-44.2%-22.3%-22.4%

Return vs Industry: MDA underperformed the Polish Healthcare Services industry which returned -23.2% over the past year.

Return vs Market: MDA underperformed the Polish Market which returned -22.5% over the past year.

Price Volatility

Is MDA's price volatile compared to industry and market?
MDA volatility
MDA Average Weekly Movement9.0%
Healthcare Services Industry Average Movement7.3%
Market Average Movement6.5%
10% most volatile stocks in PL Market11.9%
10% least volatile stocks in PL Market4.1%

Stable Share Price: MDA is more volatile than 75% of Polish stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: MDA's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Polish stocks.

About the Company

FoundedEmployeesCEOWebsite
201028Krzysztof Medralahttps://medapp.pl

MedApp S.A. develops mobile solutions for medicine in Poland. It offers CARNA LIFE, an analytical telemedicine system that enables patients to record their tests, as well as doctors to interpret the recorded tests. The CARNA LIFE product includes Carna Life Lite module, an application to record tests; and Carna Life Pro and Carna Life System modules that allow doctors to diagnose patients and monitor the state of their diabetes, high blood pressure, fever or hypothermia, atrial fibrillation, tachycardia, or cardiac arrhythmia.

MedApp Fundamentals Summary

How do MedApp's earnings and revenue compare to its market cap?
MDA fundamental statistics
Market Capzł135.07m
Earnings (TTM)zł4.02m
Revenue (TTM)zł13.73m

33.6x

P/E Ratio

9.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MDA income statement (TTM)
Revenuezł13.73m
Cost of Revenuezł3.20m
Gross Profitzł10.53m
Other Expenseszł6.52m
Earningszł4.02m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 12, 2022

Earnings per share (EPS)0.016
Gross Margin76.70%
Net Profit Margin29.24%
Debt/Equity Ratio0.0%

How did MDA perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is MDA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MDA?

Other financial metrics that can be useful for relative valuation.

MDA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue9.8x
Enterprise Value/EBITDA21.9x
PEG Ratio0.8x

Price to Earnings Ratio vs Peers

How does MDA's PE Ratio compare to its peers?

MDA PE Ratio vs Peers
The above table shows the PE ratio for MDA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average9.1x
SNT Synektik Spólka Akcyjna
22.6xn/azł238.0m
BMX BioMaxima
4.2xn/azł119.3m
VOX Voxel
5.7xn/azł373.9m
MRC Mercator Medical
3.9xn/azł646.3m
MDA MedApp
33.6x43.6%zł135.1m

Price-To-Earnings vs Peers: MDA is expensive based on its Price-To-Earnings Ratio (33.6x) compared to the peer average (9.1x).


Price to Earnings Ratio vs Industry

How does MDA's PE Ratio compare vs other companies in the European Healthcare Services Industry?

Price-To-Earnings vs Industry: MDA is expensive based on its Price-To-Earnings Ratio (33.6x) compared to the European Healthcare Services industry average (33.1x)


Price to Earnings Ratio vs Fair Ratio

What is MDA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MDA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio33.6x
Fair PE Ratio33x

Price-To-Earnings vs Fair Ratio: MDA is expensive based on its Price-To-Earnings Ratio (33.6x) compared to the estimated Fair Price-To-Earnings Ratio (33x).


Share Price vs Fair Value

What is the Fair Price of MDA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: MDA (PLN0.54) is trading below our estimate of fair value (PLN2.53)

Significantly Below Fair Value: MDA is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is MedApp forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

6/6

Future Growth Score 6/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


43.6%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MDA's forecast earnings growth (43.6% per year) is above the savings rate (2.6%).

Earnings vs Market: MDA's earnings (43.6% per year) are forecast to grow faster than the Polish market (7.6% per year).

High Growth Earnings: MDA's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: MDA's revenue (34.2% per year) is forecast to grow faster than the Polish market (5.5% per year).

High Growth Revenue: MDA's revenue (34.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MDA's Return on Equity is forecast to be high in 3 years time (29.5%)


Discover growth companies

Past Performance

How has MedApp performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


69.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MDA has a high level of non-cash earnings.

Growing Profit Margin: MDA's current net profit margins (29.2%) are lower than last year (32.1%).


Past Earnings Growth Analysis

Earnings Trend: MDA has become profitable over the past 5 years, growing earnings by 69.3% per year.

Accelerating Growth: MDA's earnings growth over the past year (57.3%) is below its 5-year average (69.3% per year).

Earnings vs Industry: MDA earnings growth over the past year (57.3%) exceeded the Healthcare Services industry -1.7%.


Return on Equity

High ROE: MDA's Return on Equity (16%) is considered low.


Discover strong past performing companies

Financial Health

How is MedApp's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: MDA's short term assets (PLN21.2M) exceed its short term liabilities (PLN6.4M).

Long Term Liabilities: MDA's short term assets (PLN21.2M) exceed its long term liabilities (PLN5.7K).


Debt to Equity History and Analysis

Debt Level: MDA is debt free.

Reducing Debt: MDA had no debt 5 years ago.

Debt Coverage: MDA has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: MDA has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is MedApp current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate MDA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MDA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MDA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MDA's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MDA has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

4.2yrs

Average board tenure


CEO

Krzysztof Medrala

no data

Tenure

zł600,000

Compensation

Mr. Krzysztof Medrala serves as Chairman of the Management Board at MedApp S.A. He serves as Member of Supervisory Board at Comperia.pl S.A. He was CEO of Origin - Investment Fund Company.Earlier he serve...


Board Members

Experienced Board: MDA's board of directors are considered experienced (4.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

MedApp S.A.'s employee growth, exchange listings and data sources


Key Information

  • Name: MedApp S.A.
  • Ticker: MDA
  • Exchange: WSE
  • Founded: 2010
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Implied Market Cap: zł135.072m
  • Shares outstanding: 250.13m
  • Website: https://medapp.pl

Number of Employees


Location

  • MedApp S.A.
  • Armii Krajowej 25
  • Kraków
  • 30-150
  • Poland

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/10 00:00
End of Day Share Price2022/08/10 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.